0001104659-22-098950.txt : 20220909
0001104659-22-098950.hdr.sgml : 20220909
20220909170302
ACCESSION NUMBER: 0001104659-22-098950
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220907
FILED AS OF DATE: 20220909
DATE AS OF CHANGE: 20220909
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rubin Eyal
CENTRAL INDEX KEY: 0001721411
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33357
FILM NUMBER: 221236776
MAIL ADDRESS:
STREET 1: C/O BRAINSTORM CELL THERAPEUTICS INC.,
STREET 2: 3 UNIVERSITY PLAZA DRIVE, STE 320
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc.
CENTRAL INDEX KEY: 0001006281
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 650643773
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 UNIVERSITY PLAZA
STREET 2: SUITE 100
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
BUSINESS PHONE: 201-696-9345
MAIL ADDRESS:
STREET 1: 2 UNIVERSITY PLAZA
STREET 2: SUITE 100
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
FORMER COMPANY:
FORMER CONFORMED NAME: ORTHODONTIX INC
DATE OF NAME CHANGE: 19980422
FORMER COMPANY:
FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP
DATE OF NAME CHANGE: 19960124
4
1
tm2225460-7_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-09-07
0
0001006281
Protalix BioTherapeutics, Inc.
PLX
0001721411
Rubin Eyal
C/O PROTALIX BIOTHERAPEUTICS, INC.
2 SNUNIT STREET SCIENCE PARK, POB 455
CARMIEL
L3
2161401
ISRAEL
0
1
0
0
Sr. VP and CFO
Stock Options (Right to Buy)
1.03
2022-09-07
4
A
0
350000
0
A
2032-09-07
Common Stock
350000
350000
D
The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
Does not include options to purchase 80,000 shares of common stock at an exercise price equal to $2.00 per share that expire on September 22, 2029.
/s/ Eyal Rubin
2022-09-09